Current and emerging strategies in the management of venous thromboembolism: Benefit–risk assessment of dabigatran

11Citations
Citations of this article
83Readers
Mendeley users who have this article in their library.

Abstract

Venous thromboembolism (VTE) is a disease state that carries significant morbidity and mortality, and is a known cause of preventable death in hospitalized and orthopedic surgical patients. There are many identifiable risk factors for VTE, yet up to half of VTE incident cases have no identifiable risk factor and carry a high likelihood of recurrence, which may warrant extended therapy. For many years, parenteral unfractionated heparin, low-molecular weight heparin, fondaparinux, and oral vitamin K antagonists (VKAs) have been the standard of care in VTE management. However, limitations in current drug therapy options have led to suboptimal treatment, so there has been a need for rapid-onset, fixed-dosing novel oral anticoagulants in both VTE treatment and prophylaxis. Oral VKAs have historically been challenging to use in clinical practice, with their narrow therapeutic range, unpredictable dose responsiveness, and many drug–drug and drug–food interactions. As such, there has also been a need for novel anticoagulant therapies with fewer limitations, which has recently been met. Dabigatran etexilate is a fixed-dose oral direct thrombin inhibitor available for use in acute and extended treatment of VTE, as well as prophylaxis in high-risk orthopedic surgical patients. In this review, the risks and overall benefits of dabigatran in VTE management are addressed, with special emphasis on clinical trial data and their application to general clinical practice and special patient populations. Current and emerging therapies in the management of VTE and monitoring of dabigatran anticoagulant-effect reversal are also discussed.

Cited by Powered by Scopus

Platelets are versatile cells: New discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond

251Citations
N/AReaders
Get full text

Reversing anticoagulant effects of novel oral anticoagulants: Role of ciraparantag, andexanetalfa, and idarucizumab

92Citations
N/AReaders
Get full text

Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases

45Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Fanola, C. L. (2015, May 27). Current and emerging strategies in the management of venous thromboembolism: Benefit–risk assessment of dabigatran. Vascular Health and Risk Management. Dove Medical Press Ltd. https://doi.org/10.2147/VHRM.S62595

Readers over time

‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24‘2506121824

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 25

66%

Researcher 8

21%

Lecturer / Post doc 4

11%

Professor / Associate Prof. 1

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 38

79%

Nursing and Health Professions 5

10%

Agricultural and Biological Sciences 3

6%

Pharmacology, Toxicology and Pharmaceut... 2

4%

Save time finding and organizing research with Mendeley

Sign up for free
0